Clinical Trial Update: Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants [Phase 3]

View source ↗

Summary

Phase 3 study evaluating immunogenicity and safety of a booster dose of monovalent glycoprotein-conjugated Hib vaccine in healthy infants aged 365-569 days; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Infection

Drugs mentioned

• Monovalent glycoprotein-conjugated Hib vaccine (Diphtheria Toxin-CRM197)

Snippet

Sponsor: Novartis Vaccines | Conditions: Haemophilus Influenzae Type b (Hib) Infection | Phase 3 | Status: COMPLETED